^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + fexagratinib (ABSK091) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies
Published date:
09/28/2019
Excerpt:
PD-L1+ve patients are 41% in durvalumab arm, 38% (Vistusertib + durvalumab arm), 29% (AZD4547 + durvalumab) and 20% (AZD4547). Durvalumab monotherapy (n = 29) had an ORR of 28%, Vistusertib + durvalumab (21%), AZD4547 + durvalumab (39%), and AZD4547 (20%) (table).
